Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: No clear relationship with levels of tumor necrosis factor

Inflammation

Volumn 22, Issue 5, 1998, Pages 483-491

  Blann, Andrew D ^a   McCollum, Charles N ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE;

AGED; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA; VON WILLEBRAND FACTOR;

EID: 0031769025     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022346010304     Document Type: Article

References (25)

1. JONASSON, L., J. HOLM, O. SKALLI, G. BONDJERS, and G. K. HANSSON. 1986. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6:131-138.
2. LIBBY, P., and G. K. HANSSON. 1991. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Investigation, 64:5-15.
3. WARNER, S. J. C., and P. LIBBY. 1989. Human vascular smooth muscle cells: target for and source of tumour necrosis factor. J Immunol. 142:100-109.
4. LANGLER, E. G., W. FIERS, and V. W. M. VAN HINSBERG. 1991. Effects of tumour necrosis factor on prostacyclin production and the harrier function of human endothelial cell monolayers. Arteriosclerosis. Thromb. 11:872-881.
5. ROBAYE, B., R. MOSSELAMNS, W. FIERS, J. E. DUMONT, and P. GALAND. 1991. Tumour necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am. J. Pathol. 138:447-453.
6. THORNHILL, M. H., S. M. WELLICOME, D. L. MAHIOUZ, J. S. S. LANCHBURY, U. KYAN-AUNG, and D. O. HASKARD. 1991. Tumour necrosis factor combines with IL-4 or IFN gamma to selectively enhance endothelial cell adhesiveness for T cells. J. Immunol. 146:592-598.
7. TIPPING, P. G., and W. W. HANCOCK. 1994. Production of tumour necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am. J. Pathol. 142:1721-1782.
8. K. VADDI, F. A. NICOLINI, P. MEHTA, and J. L. MEHTA. 1994. Increased secretion of tumour necrosis factor alpha and interferon gamma by mononuclear leukocytes in patients with ischaemic heart disease. Circulation 90:694-699.
9. VAN DER POLL, T., S. J. H. VAN DEVENTER, G. PASTERKAMP, J. A. VAN MOURIK, H. R. BULLER, and J. W. TEN CATE. 1992. Tumour necrosis factor induces von Willebrand factor release in healthy humans. Thromb. Haemostas. 67:623-626.
10. ROTHE, J., G. GEHR, H., LOETSCHER, W., and LESSLAUER. 1992. Tumour necrosis factor receptors - structure and function. Immunul. Res. 11:81-90.
11. BAZZONI, F., and B. BEUTLER. 1996. The tumour necrosis factor ligand and receptor families. New Engl. J. Med. 334:1717-1725.
12. SCANNELL, G., K. WAXMAN, G. J. KAML, G. IOLO, T. GATANAGA, R. YAMAMOTO, and G. A. GRANGER. 1993. Hypoxia induces a human macrophage cell line to release tumour necrosis factor alpha and its soluble receptors in vitro. J. Surg. Res. 54:281-285.
13. COPE, A. P., D. ADERKA, D. WALLACH, M. KAHAN, N. R. CHU, F. M. BRENNAN, and M. FELDMANN. 1995. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 84:21-30.
14. ADERKA, D., A. WYSENBEEK, H. ENGLEMANN, A. P. COPE, F. BRENNAN, Y. MOLAD, V. HORNIK, Y. LEVO, R. M. MAINI, M. FELDMANN, and D. WALLACH. 1993. Correlation between serum levels of soluble tumour necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 6:1111-1120.
15. LANGKOPF, F., and J. ATZPODIEN. 1994. Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet 344:57-58.
16. ENGLEMANN, H., D. ADERKA, M. RUBENSTEIN, D. ROTMAN, and D. WALLACH. 1989. A tumour necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumour necrosis factor toxicity. J. Biol. Chem. 264:11966-11973.
17. TANNENBAUM, S. H., and H. R. GRALNICK. 1990. Gamma interferon modulates von Willebrand factor release by cultured human endothelial cells. Blood 75:2177-2184.
18. LIP, G. Y. H., and A. D. BLANN. 1997. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res. 34:255-265.
19. POTTINGER, B. E., R. C. READ, E. M. PALEOLOG, P. G. HIGGINS, and J. D. PEARSON. 1989. Von Willebrand factor is an acute phase reactant in man. Thromb. Res. 53:387-394.
20. World Medical Association Declaration of Helsinki. 1997. Cardiovasc. Res. 35:2-3.
21. SHORT, P. E., C. E. WILLIAMS, A. M. PICKEN, and F. G. H. HILL. 1982. Factor VIII related antigen: an improved immunoassay. Med. Lab. Sci. 39:351-355.
22. ALTMAN, D. G. In: Practical Statistics for Medical Research. Chapman and Hall, London. 1991. 455-460.
23. LANTZ, M., S. MALIK, M. L. SLEVIN, and I. OLSSON. 1992. Infusion of tumour necrosis factor causes an increase in circulating TNF-binding protein in humans. Cytokines 2:402-406.
24. BOEHME, M. W. J., R. WALDHERR, A. KIST, S. RIEDL, R. WALTER-KIRST, J. KEMPENI, and U. RAETH. 1996. Kinetics of soluble TNF-receptors and soluble adhesion molecules ICAM-1, E-selectin and VCAM-1 under systemic rhTNF-alpha therapy. Eur. J. Clin. Invest. 26:404-410.
25. PALEOLOG, E. M., M. A. CAREW, and J. D. PEARSON. 1991. Effects of tumour necrosis factor and interleukin-1 on von Willebrand factor secretion from human vascular endothelial cells. Int. J. Radiat. Biol. 60:279-285.